News

Exciting Data From Moderna's Skin Cancer Treatment Trials

Exciting Data From Moderna's Skin Cancer Treatment Trials

Moderna Unveils New Insights on Skin Cancer Treatment

Moderna Inc (NASDAQ: MRNA) has made waves in the oncology sector by revealing groundbreaking findings from its clinical trials. The data, focusing on mRNA-4359 in tandem with pembrolizumab, shows promise for patients battling checkpoint inhibitor-resistant melanoma.

What Is mRNA-4359?

This innovative therapy, mRNA-4359, aims at tackling immune evasion in cancer cells by triggering specific T cell responses. It's designed to target common pathways involved in immune resistance, PD-L1 and IDO1, which can often shield tumors from the body's natural defenses.

Phase 1/2 Study Findings

The recent analysis included 29 participants who were administered mRNA-4359 at doses of either 400 µg or 1,000 µg through intramuscular injections every three weeks, up to nine doses. Results indicated an impressive objective response rate (ORR) of 24%, while the disease control rate (DCR) rose to 60%, demonstrating effective control over tumor progression.

Encouraging Response Rates

Among participants whose tumors expressed PD-L1 (TPS?1%), the ORR was even more remarkable, reaching 67%. This subset of patients exhibited notable growth in specific peripheral T cell responses, and novel T cell receptor clones emerged as a result of the treatment, highlighting its potential to adapt to various cancer strains.

Safety Profile of the Combination Therapy

Both mRNA-4359 and pembrolizumab maintained a manageable safety profile. Notably, no new immune-related adverse events were recorded during the therapy, which is promising for future applications. This finding could pave the way for broader use of mRNA-4359 in combination therapies.

Ongoing Clinical Trials

Currently, mRNA-4359 is being further investigated not only as a mono-therapy but also in combinations with pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC). This ongoing study signifies a step forward in understanding how mRNA therapies could transform cancer treatment paradigms.

Recent Developments

In addition to its skin cancer endeavors, Moderna has released preliminary data on their COVID-19 vaccine, mNEXSPIKE, for the upcoming 2025-2026 vaccination cycle. This new vaccine version is reported to also effectively target recent SARS-CoV-2 variants. Early trials showed over a 16-fold increase in neutralizing antibodies in key demographics, including adults with underlying health conditions.

Market Performance

As of the latest updates, MRNA stock witnessed a rise of 3.54%, trading at approximately $27.78. This uptick reflects investor confidence following the positive data released regarding the mRNA-4359 therapy as well as ongoing innovations.

Frequently Asked Questions

What is mRNA-4359 and how does it work?

mRNA-4359 is a targeted cancer antigen therapy that aims to provoke T cell responses against tumors using key pathways responsible for immune evasion.

What were the key findings in the recent study involving mRNA-4359?

The study highlighted a 24% objective response rate and a 60% disease control rate among participants, with even higher rates observed in specific tumor types.

Is combination therapy with pembrolizumab safe?

Yes, the combination therapy showed a manageable safety profile without new immune-related adverse events, suggesting a favorable safety record.

Are there ongoing clinical trials for mRNA-4359?

Absolutely, mRNA-4359 is currently under investigation in ongoing Phase 1/2 studies both as a monotherapy and in combination with pembrolizumab for melanoma and lung cancer.

How is Moderna performing in the stock market?

Following the positive updates from their studies, Moderna's stock (MRNA) has seen a recent increase, indicating strong investor interest and confidence.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 29

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 166

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 89

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 101

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 93

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 74

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading

Top 5 Most Recently Viewed Articles

Xometry Prepares for Financial Report Ahead of Market Opening

Updated Category News Views 175

Xometry Financial Results Announcement Overview Xometry, Inc. (NASDAQ: XMTR), recognized as a leading AI-powered marketplace for manufacturing services, is gearing up to announce its fourth quarter and full year 2024 financial results. The report is expected to be made available before trading opens on the market. This announcement represents a significant opportunity for...

Continue Reading
Warren Buffett's Surprising Bet on the RV Industry Pays Off

Updated Category News Views 1216

Warren Buffett's Unconventional Investment Journey Warren Buffett, known for his wisdom in investing, made a surprising decision that changed the game for Berkshire Hathaway Inc. He chose to invest in Forest River, an RV manufacturer, despite having little knowledge of the industry. This significant move, spearheaded by the late founder Pete Liegl, proved to be highly...

Continue Reading
BizClik Media Unveils September Editions of Key Industry Magazines

Updated Category News Views 201

BizClik Media Unveils September Editions of Key Publications This September, the latest editions of Supply Chain Digital, Procurement Magazine, and Manufacturing Digital have been published, featuring engaging interviews with industry leaders and experts from prominent companies. Spotlighting Industry Leaders This month's issues highlight a variety of thought-provoking...

Continue Reading
Ascletis Unveils Breakthrough Findings for ASC30 Injection

Updated Category News Views 210

Exciting Developments in Obesity Treatment with ASC30 In the realm of obesity management, Ascletis Pharma Inc. has made significant strides with their investigational drug ASC30, a promising GLP-1 receptor (GLP-1R) agonist designed for both oral and subcutaneous use. Preliminary results from their Phase Ib trial conducted in the U.S. indicate a fascinating half-life of 36...

Continue Reading
CBIZ Welcomes Kathy Raffa to Its Board of Directors

Updated Category News Views 204

CBIZ Strengthens Board with New Appointment CBIZ, Inc. (NYSE: CBZ), a prominent national professional services advisor, has recently announced the addition of Kathy Raffa to its Board of Directors. This strategic appointment, effective January 15, 2025, follows CBIZ's recent acquisition of the non-attest assets of Marcum. This move is seen as a testament to the...

Continue Reading